Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb’s nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. This combination study is an amendment to the Company’s ongoing Phase1/2a study of [212Pb]VMT01 in patients with metastatic melanoma. The study has completed enrollment in the first cohort and has commenced dosing in the second cohort. Under the terms of the collaboration, Perspective will sponsor and fund the combination study and Bristol Myers Squibb will provide nivolumab for use in the study. “We see great potenti
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc. [Yahoo! Finance]Yahoo! Finance
- Perspective Therapeutics to Participate at Upcoming April Investor ConferencesGlobeNewswire
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsGlobeNewswire
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024GlobeNewswire
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityGlobeNewswire
CATX
Earnings
- 11/14/23 - In-Line
CATX
Sec Filings
- 4/24/24 - Form 4
- 4/19/24 - Form SC
- 4/18/24 - Form DEFA14A
- CATX's page on the SEC website